

WITNESS - CA209-9GY (dernière mise à jour : 25/11/2019)

[ARCHIMAIDindex.php?action=show&id=176](#)

Informations générales

Titre de l'étude : A National, Prospective, Non-Interventional Study of Nivolumab (BMS-936558) in Patients With Advanced Renal Cell Carcinoma in Second or Third Line Setting in Real Life

Traitement : Métastatique ou localement avancé

Type d'étude : Qualité de vie / Observationnelle

Phase : NA **Stade** : Localement avancé à Métastatique **Ligne(s)** : 2, 3

Schéma : This is a French, nationwide, prospective, observational, multicenter study in participants diagnosed with renal cell carcinoma, who start a new systemic therapy with nivolumab for the first time and within the market authorization approval, following a first or second-line therapy.

Spécialités / Localisations

Spécialité n°1 : Voies urinaires

CIM10 - Localisation n°1 : C64 - Tumeur maligne du rein, à l'exception du bassinnet

Critères

Critères d'inclusion : Liste non exhaustive

- Adult patients with the diagnosis of advanced RCC (histologically or cytologically) whose physician has already decided to initiate a treatment with nivolumab as second or third line therapy for the first time for the treatment of RCC, according to the label approved in France

Critères de non-inclusion : Liste non exhaustive

- Patients with a primary diagnosis of a cancer other than advanced RCC within the past five years, ie, a cancer other than RCC that requires systemic or other treatment
- Patients previously treated with anti-PD1, anti-PDL1 or anti-CTLA4 therapy
- Patients currently included in an interventional clinical trial for their advanced or RCC. Patients who have completed their participation in an interventional trial; or who are not receiving study drug anymore and who are only followed-up for OS can be enrolled

Informations promoteur

Nom du promoteur : BRISTOL MYERS SQUIBB

Type de promoteur : Industriel

Adresse : BRISTOL MYERS SQUIBB - 00000 HORS FRANCE

Coordonnateur : - *Mail :* - *Tél :*

Informations centre investigateur n°1

Nom du centre : ILC Maurice Tubiana

Adresse : 20 Avenue du Capitaine Guynemer 14000 CAEN

Investigateur : Emmanuel SEVIN

TEC / ARC / IDE : Aline MEZERGUES - *Mail :* guillaume.3c@gmail.com - *Tél :*

Ouverture de l'essai : CLOS

Liens utiles

ClinicalTrials : <https://clinicaltrials.gov/ct2/show/NCT03455452?cond=Renal+Cancer&titles=936558&cntry=FR&rank=1>